Ian F. Smith - 08 Oct 2025 Form 4 Insider Report for Stoke Therapeutics, Inc. (STOK)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: STOK
Reported as of: 08 Oct 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Oct 2025, 16:16:10 UTC
Prior SEC filing: 07 Oct 2025
Next SEC filing: 07 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Jonathan Allan, Attorney-in-Fact

Key filing fact

Ian F. Smith filed Form 4 for Stoke Therapeutics, Inc. (STOK) on 14 Oct 2025.

Key facts

This page summarizes Ian F. Smith's Form 4 filing for Stoke Therapeutics, Inc. (STOK).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 14 Oct 2025, 16:16.

Change

Previous filing in this sequence was filed on 07 Oct 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001197032 Primary reporting owner

SMITH IAN F

Relationship: Chief Executive Officer, Director
Address: C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVENUE, BEDFORD
Signature: /s/ Jonathan Allan, Attorney-in-Fact
Signature date: 14 Oct 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

STOK transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +570,000
Change %
Price: $0.000000
Shares after: 570,000
Date: 08 Oct 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 570,000
Exercise price: $30.50
Footnotes: F1

STOK transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +380,000
Change %
Price: $0.000000
Shares after: 380,000
Date: 08 Oct 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 380,000
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The option shall vest as to 1/4 of the total award on October 6, 2026, with an additional 1/48 of the total award vesting monthly thereafter, subject to the reporting person's continued service to the Issuer on each vesting date.

Footnote F2

Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.

Footnote F3

The award shall vest as to 1/4 of the total award annually on the sixth calendar day of October, subject to the reporting person's continued service to the Issuer on each vesting date, with the first tranche vesting on October 6, 2026.